Page last updated: 2024-11-06

lurtotecan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lurtotecan is a potent topoisomerase I inhibitor that exhibits significant antitumor activity. It is a camptothecin analog that targets the enzyme responsible for DNA replication and repair, preventing the proper separation of DNA strands. Lurtotecan is studied for its potential to treat various cancers, including colorectal, small cell lung, and ovarian cancer. Its mechanism of action involves trapping the DNA-topoisomerase I complex, leading to DNA damage and ultimately cell death. Lurtotecan is administered intravenously and has shown promising results in clinical trials for several cancer types. Further research is ongoing to optimize its therapeutic efficacy and minimize potential side effects.'

lurtotecan: NX-211 is the low-clearance liposomal formulation; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60956
CHEMBL ID341028
CHEMBL ID305666
SCHEMBL ID19208
MeSH IDM0242259

Synonyms (43)

Synonym
bdbm50036130
8-ethyl-8-hydroxy-15-(4-methylhexahydro-1-pyrazinylmethyl)-(8s)-2,3,8,9,12,14-hexahydro-11h-[1,4]dioxino[2,3-g]pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-9,12-dione with trifluoroaceticacid
nx-211
gi-147211
gw-211
lurtotecan
gg-211
osi-211
11h-1,4-dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8h,14h)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8s)-
lurtotecan [inn]
gi 147211
nx 211
gg 211
osi 211
CHEMBL341028 ,
CHEMBL305666
nx211 cpd
149882-10-0
gl-147211c
gi147211
osi211
gg211
gl 147211c
7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(s)-camptothecin
4j1l80t08i ,
unii-4j1l80t08i
gl147211c
(8s)-8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-11h-p-dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8h,14h)-dione
lurtotecan [who-dd]
11h-1,4-dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8h,14h)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (s)
SCHEMBL19208
d-myo-inositol2,4,5-trisphosphate,hexaammoniumsalt
DTXSID30164422
DB12222
(s)-8-ethyl-8-hydroxy-15-((4-methylpiperazin-1-yl)methyl)-11,14-dihydro-2h-[1,4]dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12(3h,8h)-dione
gg 211; gi 147211; lurtotecan; nx 211; osi 211
Q6704977
(18s)-18-ethyl-18-hydroxy-2-[(4-methylpiperazin-1-yl)methyl]-6,9,20-trioxa-13,24-diazahexacyclo[12.11.0.03,12.05,10.015,24.017,22]pentacosa-1,3,5(10),11,13,15,17(22)-heptaene-19,23-dione
A936765
(s)-8-ethyl-8-hydroxy-15-((4-methylpiperazin-1-yl)methyl)-2,3,11,14-tetrahydro-12h-[1,4]dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12(8h)-dione
MS-29621
HY-13670
CS-0007547

Research Excerpts

Overview

Lurtotecan is a clinically active water-soluble camptothecin analogue that has been formulated into a low-clearance unilamellar liposome, NX 211.

ExcerptReferenceRelevance
"Lurtotecan is a clinically active water-soluble camptothecin analogue that has been formulated into a low-clearance unilamellar liposome, NX 211. "( Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
Baccanari, D; Bendele, R; Brown, E; Chiang, S; Desjardins, JP; Dihel, LC; Emerson, DL; Gill, SC; Hamilton, M; LeRay, JD; Luzzio, MJ; Moon-McDermott, L; Moynihan, K; Richardson, FC; Tomkinson, B, 2000
)
1.96

Pharmacokinetics

ExcerptReferenceRelevance
" The plasma pharmacokinetics of SPI-355 in rats were typical of those of other pegylated liposomal formulations, with significantly increased blood circulation time; the dose-corrected area under the curve and Cmax of SPI-355 (10 mg/kg) were 1250- and 35-fold higher, respectively, than those of nonliposomal GL14711C (8."( Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Amantea, M; Colbern, GT; Dykes, DJ; Engbers, C; Hiller, A; Luzzio, M; Musterer, R; Pegg, E; Saville, R; Uster, P; Weng, S; Working, PK, 1998
)
0.3
"Population pharmacokinetic-dynamic analysis was prospectively integrated in a broad phase II program of lurtotecan (GI147211), a novel camptothecin derived topoisomerase I inhibitor, to determine the population pharmacokinetic profile in a larger population, to estimate individual pharmacokinetic parameters and to investigate relationships with clinical outcome."( Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Calvert, H; Cortes-Funes, H; Dombernowsky, P; Gamucci, T; Gore, ME; Hanauske, AR; Heinrich, B; Kaye, SB; Lehnert, M; Loos, WJ; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Selinger, K; Sessa, C; van Oosterom, AT; Verweij, J; Wanders, J; Wissel, PS, 2002
)
0.76

Bioavailability

ExcerptReferenceRelevance
" We performed a study with GI147211, a new semisynthetic camptothecin analogue, to determine the absolute bioavailability of the drug given orally."( The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Creemers, GJ; de Boer-Dennert, M; DePee, S; Gerrits, CJ; Harteveld, M; Planting, AS; Pritchard, JF; Schellens, JH; Verweij, J; Wissel, P, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
"5 mg/m2/day dosing but was not cumulative."( Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
DeMaria, D; Grochow, LB; Kaye, SB; McDonald, A; O'Dwyer, PJ; Paz-Ares, L; Selinger, K; Sludden, J; Stevenson, JP; Twelves, C; Wissel, P, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID210949The compound was tested for top1-induced DNA cleavage activity; ++ indicates more potent than CPT1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
AID678800TP_TRANSPORTER: increase of cytotoxicity by GF120918 in MX3 cells2001Clinical cancer research : an official journal of the American Association for Cancer Research, Apr, Volume: 7, Issue:4
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
AID678799TP_TRANSPORTER: increase of cytotoxicity by GF120918 in T8 cells2001Clinical cancer research : an official journal of the American Association for Cancer Research, Apr, Volume: 7, Issue:4
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (42.86)18.2507
2000's20 (57.14)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.63 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (44.44%)5.53%
Reviews5 (13.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (41.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Study of NX 211 in Combination With Cisplatin Given as an IV Infusion Days 1, 2, and 3 Every 3 Weeks in Patients With Solid Tumors [NCT00006036]Phase 114 participants (Actual)Interventional2000-03-22Completed
Randomized Phase II Study Of NX 211 Given By Two Different Intravenous Schedules In Advanced And/Or Recurrent Epithelial Ovarian Cancer [NCT00010179]Phase 281 participants (Actual)Interventional2000-10-31Completed
Phase II Study Of NX 211 (Liposomal Lurtotecan) Given As An IV Bolus Injection On Days 1 and 8 Every 3 Weeks In Patients With Metastatic Or Loco-Regional Recurrent Squamous Cell Carcinoma Of The Head and Neck With Target Lesions Within Previously Irradiat [NCT00022594]Phase 250 participants (Actual)Interventional2001-05-31Completed
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer [NCT00046787]Phase 247 participants Interventional2002-09-30Completed
A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer [NCT00046800]Phase 280 participants Interventional2002-09-30Completed
A Phase I Study of NX211 Given as an IV Infusion Days 1, 2 and 3 Every 3 Weeks in Patients With Solid Tumors [NCT00003891]Phase 137 participants (Actual)Interventional1999-02-25Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]